TrivarX Limited (MDBIF)
OTCMKTS
· Delayed Price · Currency is USD
0.0021
-0.0048 (-69.57%)
At close: Dec 19, 2024
TrivarX Revenue
TrivarX had revenue of 1.13M AUD in the half year ending December 31, 2024, with 17.55% growth. This brings the company's revenue in the last twelve months to 2.00M, up 9,105.58% year-over-year. In the fiscal year ending June 30, 2024, TrivarX had annual revenue of 888.83K, down -7.46%.
Revenue (ttm)
2.00M AUD
Revenue Growth
+9,105.58%
P/S Ratio
3.55
Revenue / Employee
332.69K AUD
Employees
6
Market Cap
4.39M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 888.83K | -71.62K | -7.46% |
Jun 30, 2023 | 960.45K | -45.00K | -4.48% |
Jun 30, 2022 | 1.01M | -258.10K | -20.43% |
Jun 30, 2021 | 1.26M | 338.28K | 36.56% |
Jun 30, 2020 | 925.27K | -3.18M | -77.44% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.76B |
Veradigm | 588.02M |
Glass House Brands | 200.90M |
Northwest Biotherapeutics | 1.38M |
Elite Pharmaceuticals | 70.00M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
Silence Therapeutics | 43.26M |